BRAF — a tumour-agnostic drug target with lineage-specific dependencies
Memorial Sloan Kettering Cancer Center · Cornell University
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
119
total citations
- FWCI
- 24.90
- Percentile
- 100%
- References
- 294
Citations per year
Authors
4Topics & keywords
Topics
Keywords
- Trametinib
- Dabrafenib
- MEK inhibitor
- Cancer research
- Medicine
- Drug resistance
- Vemurafenib
- Population
No related works found for this paper.
Funding
- ELEli Lilly and Company
- PPfizerAward: P30 CA008748
- MSMemorial Sloan-Kettering Cancer CenterAward: CA008748
- CFCycle for SurvivalAwards: P30 CA008748, U54 OD020355
- NINational Institutes of HealthAwards: P30 CA008748, U54 OD020355, R01 CA229624
- MAMarie-Josée and Henry R. Kravis Center for Molecular OncologyAward: P30 CA008748
- NCNational Cancer InstituteAwards: CA008748, U54 OD020355, P30 CA008748